Please provide your email address to receive an email when new articles are posted on . In the study, 67% of patients receiving upacicalcet achieved target parathyroid hormone concentrations. Overall, ...
- The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - The primary endpoint was met with 76% of participants administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback